Stay updated on Zevor-cel in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Zevor-cel in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Zevor-cel in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 has been added to the record history. The government funding lapse notice and the previous Revision: v3.4.1 have been removed.SummaryDifference0.7%

- Check21 days agoChange DetectedA banner notice about a lapse in government funding was added to the page, and the history now shows a new site revision (v3.4.1) replacing the previous version (v3.4.0).SummaryDifference0.7%

- Check28 days agoChange DetectedAdded UI elements such as showing the glossary, green and red highlights, and the revision label v3.4.0; removed the older No FEAR Act data label and the v3.3.4 revision reference.SummaryDifference0.9%

- Check42 days agoChange DetectedThe page history now shows a new version entry (v3.3.4) and removes the previous v3.3.3, reflecting a small maintenance update to the page metadata. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded revision note 'Revision: v3.3.3' and removed the older 'Revision: v3.3.2' entry; the HHS Vulnerability Disclosure footer link was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision: v3.3.2 appears to be a minor site update compared to the previous version v3.3.1, with no apparent changes to study records or their content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Zevor-cel in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zevor-cel in Relapsed/Refractory Multiple Myeloma Clinical Trial page.